Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RANBP2-type and C3HC4-type zinc finger-containing protein 1 (RBCK1), also known as HOIL-1, is an E3 ubiquitin-protein ligase and an essential component of the Linear Ubiquitin Chain Assembly Complex (LUBAC) (UniProt, 2024). LUBAC is unique in its ability to catalyze the formation of head-to-tail linear ubiquitin chains, which play a critical role in the activation of the canonical NF-kappa-B pathway and the regulation of programmed cell death (Kirisako et al., 2006). RBCK1 acts as a scaffold and regulatory subunit within this complex, ensuring the stability and specificity of linear ubiquitination on substrates like NEMO and RIPK1 (Gerlach et al., 2011). Mutations in the RBCK1 gene are associated with severe clinical phenotypes, including Polyglucosan body myopathy 1, which involves glycogen accumulation in muscles and the heart, and a combined immunodeficiency with autoinflammation (Boisson et al., 2012). In the context of oncology, RBCK1 is frequently upregulated in various malignancies, where it promotes tumor cell survival and chemoresistance by enhancing pro-survival signaling (NCBI, 2024). Consequently, RBCK1 and the LUBAC complex are being investigated as potential therapeutic targets for the development of novel anti-inflammatory and anti-cancer agents.
Inhibition of linear ubiquitin chain assembly complex (LUBAC) activity and subsequent NF-kappa-B signaling pathway suppression.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RANBP2-type and C3HC4-type zinc finger-containing protein 1 (RBCK1).